Braxia Scientific (Seite 3)

[Shanghai2006]

Braxia Scientific Reports Fourth Quarter and FY 2022 Financial Results
29. July 2022

Fiscal 2022 Financial Summary
The Company's cash and cash equivalents as of March 31, 2022 was $8.6 million compared with December 31, 2021 at $7.64 million reflecting the impact of a private placement the Company closed on January 31, 2022.

The Company recorded revenue of $1.49 million for the fiscal 2022 year ended March 31, 2022 compared with revenue of $1.008 million for the year ended March 31, 2021. On a year-over-year basis, revenue increased 47.5%.

In the fourth quarter of fiscal 2022, the Company recorded revenue of $369,654 compared with revenue of $246,673 in the fourth quarter of 2021. On a year-over-year basis, fourth quarter revenues increased 49.9%.

The increase in revenue primarily reflects an increase in the number of treatments from the administering of ketamine at the Braxia Health clinics in Ontario.

Net loss was $12.1 million for the year ended March 31, 2022, compared to a net loss of $88.8 million for the year ended March 31, 2021. The net loss includes a non-cash, share-based compensation of $2,422,562 (2021 - $2,874,857) and goodwill impairment of $5,275,374 (2021- $nil) related to the acquisition of the CRTCE. In the comparative period, the Company had completed a reverse-take over, the acquisition of CRTCE and completed a brokered private placement which led to an overall increase in expenditures as the business evolved. The Company's management team has focused on cost cutting and reducing certain operating expenditures to focus on the Company's core business.

https://www.prnewswire.com/news-releases/braxia-scientific-r…

[Shanghai2006]

Braxia Scientific Bolsters Leadership with Strategic Hires; Adds Chief Information Officer and Global Pharmaceutical Industry Leader as VP R&D and Growth

https://braxiascientific.com/category/news/
27.July 2022

[Shanghai2006]

1mio, es werden keine weiteren hinzukommen.
Investment: 25000 Euro

[Shanghai2006]

Braxia Scientific Expands Clinic Footprint in Canada Providing Greater Access to Network of Specialists Delivering Ketamine and Psilocybin Treatments for Depression and Related Mental Health Disorders
15 JUNE 2022

Braxia Scientific Corp. ("Braxia", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and other innovative treatments for people living with depression and related mental health disorders, is pleased to announce today the opening of its newest Braxia Health clinic in the Kitchener-Waterloo area in Ontario. The Kitchen-Waterloo location is the fifth Braxia Health Clinic in Canada.

"Today's announcement is the first of what we intend to be a series of growth developments and acquisitions to our clinical network," said Braxia CEO Dr. Roger McIntyre. "Further plans are in place for the expansion of Braxia Health clinics in Toronto and Ottawa, Ont., to better serve the growing unmet need in our Canadian communities.

https://greenstocknews.com/news/otcmkts/braxf/braxia-scienti…

[Shanghai2006]

Braxia Scientific Presents Positive Preliminary Findings from Phase II Randomized, Multi-Dose Clinical Trial of Psilocybin-Assisted Therapy for Treatment Resistant Depression

TORONTO, June 2, 2022 / Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing and advancing innovative ketamine and psilocybin treatments for depression and related mental health disorders, is pleased to announce positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial to evaluate the feasibility, safety, tolerability, and efficacy of multi-dose psilocybin-assisted therapy for Treatment-Resistant-Depression. The preliminary results were presented at the “From Research to Reality Conference” in Toronto, May 27-28, 2022. Positive Preliminary Results Highlights Braxia Scientific’s ongoing multi-dose psilocybin trial effectively demonstrated the feasibility of Braxia’s proprietary psilocybin-assisted therapy protocol with high rates of recruitment and retention with adequate tolerability and safety. Clinically meaningful improvements in depression severity observed (as measured by the MADRS1) with complete analysis of antidepressant efficacy and...

https://braxiascientific.com/category/news/

[Shanghai2006]

Therapy for Depression in Ontario

Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression in Ontario

Health Canada approval is for a patient with the indication of Major Depressive Disorder, in the absence of terminal medical illness or end of life distress.
Approval marks Braxia’s first Special Access Program (SAP) approval for use of psilocybin in Ontario.
To date Braxia’s experienced therapists have delivered psilocybin-assisted therapy treatments to 16 individuals with depression through its proprietary clinical trial commenced late 2021.

https://braxiascientific.com/news/braxia-scientific-receives…
Published on May 20, 2022

[Shanghai2006]

https://cannabishealthnews.co.uk/2022/04/19/nine-out-of-10-c…
Data collected from over 2,000 patients shows the effectiveness of medical cannabis for managing chronic pain.
Published on 19th April 2022
By Sarah Sinclair

[Shanghai2006]

Braxia Scientific Corp. Announces Resignation of David Greenberg as Director (13.April2022)

https://psychedelicreview.com/organization/braxia-scientific…

[Shanghai2006]

Braxia Scientific Corp. Reaches Agreements to Settle Class Actions in US and Canada
13th April 2022

Braxia Scientific Corp. announced that it has reached an agreement in principle (the "US Settlement") to settle claims alleged in a securities class action ("US Class Action") pending against the Company and certain of its former officers filed in the United States District Court for the Central District of California in April, 2021. The Company also announced it has signed a settlement agreement (the "Canadian Settlement") to resolve a class action lawsuit ("Canadian Class Action") that was filed in the British Columbia Supreme Court in May 2021 against the Company its CEO, certain of its former officers, a shareholder, and underwriters. The US Settlement contemplates a cash payment by the Company of USD 1 million to settle the US Class Action.
The Canadian Settlement contemplates a cash payment of CAD 1.9 million, of which the Company will be paying CAD 1.6 million. After available insurance, the total cost to the Company to settle both class actions will be approximately CAD 1.36 million. This does not include legal expenses incurred by the Company, estimated at approximately CAD 950,000, of which approximately CAD 750,000 has been paid. Both the US Settlement and the Canadian Settlement are subject to court approval at hearings expected later in 2022.
Under the respective settlement agreement, once the US Settlement and the Canadian Settlement receive court approval, both class actions will be dismissed against all defendants, including the Company and its officers. Approval by the respective courts, notice to the putative classes, and the satisfaction of customary conditions to effectiveness will take several months. As previously disclosed, given the uncertainties of litigation, the Company had not been in a position to assess the likelihood of any potential loss or adverse effect on its financial condition or to reasonably estimate the amount of potential loss in connection with the class actions. As a result of the entry into the US Settlement and the Canadian Settlement, the Company expects that the above-referenced total cost to settle will be incorporated into its results of operations and financial condition for the fiscal quarter ending June 30, 2022.

[Shanghai2006]

Braxia Scientific CEO and CMO, Invited to Speak as Experts at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford April 4-6
04/01/2022 | 05:26pm EDT

TORONTO, April 1, 2022 /PRNewswire/ - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce that CEO, Dr. Roger McIntyre and Chief Medical and Scientific Officer, Dr. Josh Rosenblatt have been invited to present at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford in Oxford, England. This meeting is one of the largest International Conferences on ketamine research, development, and clinical implementation.